Physician profile
Daniel M Schwartz
NPI 1740392901
$7,980,560.99
in general payments reported to CMS, 2019-2025
8 companies · $431 in 2025
The $431 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,250 · 2020: $77K · 2021: $44K · 2022: $1,000 · 2023: $208 · 2024: $7.9M · 2025: $431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7.9M · Food and Beverage: $713 · Consulting Fee: $525 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,851,645.04 |
| Food and Beverage | $712.72 |
| Consulting Fee | $525.00 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rxsight INC | $7,980,162.79 | 2019-2025 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec, INC. | $167.62 | 2024 | Veracity Surgical |
| Genentech USA, INC. | $114.07 | 2024-2025 | Vabysmo, Susvimo |
| Alcon Vision LLC | $58.14 | 2023 | Clareon |
| Abbvie INC. | $23.56 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $19.50 | 2024 | Eylea Hd, Eylea |
| Regeneron Healthcare Solutions, INC. | $15.31 | 2024 | Eylea Hd |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,962,946.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.